Abstracts Archive - Page 1722 of 2425 - ACR Meeting Abstracts

Abstract Number: 487 • 2015 ACR/ARHP Annual Meeting
Early Rheumatoid Arthritis Patients in the Worse Disease Trajectory Group Fail to Achieve Improvement in Physical Function
Cheryl Barnabe¹, Ye Sun², Susan J. Bartlett^3,4, Gilles Boire⁵, Carol Hitchon⁶, Edward C. Keystone⁷, Boulos Haraoui⁸, J Carter Thorne², Diane Tin⁹, Janet E. Pope¹⁰, VP Bykerk¹¹ and CATCH Investigators, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Institut de Rhumatologie, Montreal, QC, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Disease trajectories in early rheumatoid arthritis (ERA) are characterized by differences in absolute levels of disease activity and rates of improvement, with patients in…
Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…
Abstract Number: 489 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Toxicity of Methotrexate Monotherapy in Daily Clinical Practice. Results from an Early Arthritis Clinic
Christian A. Waimann^1,2, Margarita Landi³, Fernando Dal Pra³, Gustavo Citera⁴, Maria Celeste Orozco⁴, Osvaldo Luis Cerda³, Federico Ceccatto⁵, Sergio Paira⁵, Francisco Colombres⁶, Alberto Berman⁷, Horacio Berman⁷, Anastasia Secco⁸, Marta Mamani⁸, Maritza Manzano⁸, Maria Victoria Martire⁸, Francisco Caeiro⁹, Maria Haye Salinas¹⁰, Alejandro J. Alvarellos¹⁰, Ana C. Alvarez¹⁰, Javier Rosa¹¹, Valeria Scaglioni¹², Enrique R. Soriano¹¹, Josefina Marcos¹³, Mercedes Argentina García¹⁴, AC Costi¹⁵, Alejandro Martinez¹⁶, Oscar Luis Rillo¹⁶, Edson Veloso¹⁷, Ricardo V. Juárez¹⁸, Maria Elena Crespo¹⁹, Ana Quinteros²⁰, Doralia Vasquez²⁰, C Ledesma²¹, Gabriela Salvatierra²¹, R Quintana²², Monica Sacnun²³ and Marcelo Abdala²⁴, ¹Rheumatology, Hospital Dr. Hector Cura, Olavarria, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁶Tucuman, Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁸Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁰Rheumatology, Hospital Privado de Córdoba, Córdoba, Argentina, ¹¹Hospital Italiano, Buenos Aires, Argentina, ¹²Rheumatology, Hospital Italiano, Buenos Aires, Argentina, ¹³HIGA San Martín, La Plata, Argentina, ¹⁴Rheumatology Unit, HIGA San Martín, La Plata, Argentina, ¹⁵Rheumatology, HIGA San Martín, La Plata, Argentina, ¹⁶Rheumatology, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, ¹⁷Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ¹⁸Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Argentina, ²⁰Centro Integral De Reumatologia, Tucumán, Argentina, ²¹Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, ²²Rheumatology, Hosp. Provincial, Rosario, Argentina, ²³Hosp. Provincial, Rosario, Argentina, ²⁴Hospital Provincial del Centenario, Santa Fe, Argentina
Background/Purpose: Several trials had reported the efficacy and toxicity of methotrexate monotherapy in patients with early rheumatoid arthritis. However, patients outside clinical trials could be…
Abstract Number: 490 • 2015 ACR/ARHP Annual Meeting
Personalizing the Treat to Target Approach in Rheumatoid Arthritis
Eric M. Ruderman¹, Jennifer Beaumont², Azra Muftic², Arthur M. Mandelin II¹, Amy Eisenstein², George J. Greene² and David Cella², ¹Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The treat to target (T2T) approach has become part of the standard of care in RA management. Implicit in this approach is patient involvement…
Abstract Number: 491 • 2015 ACR/ARHP Annual Meeting
A Paradigm Shift in the Disease Assessment of Rheumatoid Arthritis : From Blood to Urine Testing
Wan-Uk Kim¹, Yune-Jung Park², Seung-Ah Yoo³, Bong Ki Hong³, Gi myo Kim⁴, Susanna Choi⁵, Saseong Lee³ and Chul-Soo Cho⁶, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea, ³Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea, ⁴Institute of bone and joint diseases, Catholic university, seoul, South Korea, ⁵Institute of Bone and Joint diseases, The Catholic University of Korea, seoul, South Korea, ⁶Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: To optimize treatment for rheumatoid arthritis (RA), it is ideal to monitor disease activity on a daily basis such as glucose measurement since RA…
Abstract Number: 492 • 2015 ACR/ARHP Annual Meeting
Correlations Between Clinical, Laboratory and Ultrasound Joint Examination in RA Patients Treated with Rituximab
Andreea Borangiu¹, Diana Mazilu¹, Ioana Saulescu¹, Evelina Iachim², Laura Grosanu¹, Cosmin Constantinescu¹, Andra Balanescu¹, Denisa Predeteanu¹, Ruxandra Ionescu¹ and Daniela Opris¹, ¹University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Carol Davila Medicine and Pharmacy University, Bucharest, Romania
Background/Purpose: Correct assessment to biologics in rheumatoid arthritis (RA) patients is extremely important regarding future patient management. There is still an open debate about the…
Abstract Number: 493 • 2015 ACR/ARHP Annual Meeting
Diagnostic Delay in Early Arthritis: Ten Years-Experience of a Single Center
Francesca Benaglio, Silvia Balduzzi, Serena Bugatti, Garifallia Sakellariou, Carlomaurizio Montecucco and Roberto Caporali, Division of Rheumatology, University of Pavia, IRCCS S. Matteo Foundation, Pavia, Italy, Pavia, Italy
Background/Purpose: In the last 10 years a big effort has been made to reduce the diagnostic delay in patients with early arthritis, in order to…
Abstract Number: 494 • 2015 ACR/ARHP Annual Meeting
High C-Reactive Protein at Baseline Is Associated with Long-Term Treatment Persistence in Patients with Rheumatoid Arthritis Treated with Rituximab
Maria Joao Gonçalves^1,2, Geraldine Cambridge³ and Maria J. Leandro³, ¹Rheumatology Department, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, ²Rheumatology Department, Lisbon Academic Medical Centre, Lisbon, Portugal, ³Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom
Background/Purpose: B cell depletion with rituximab (RTX) is an established treatment for RA. It was first introduced at UCL in 1998 and at this centre…
Abstract Number: 495 • 2015 ACR/ARHP Annual Meeting
Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy
Antonio Manzo¹, Serena Bugatti¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Barbara Vitolo¹, Carlomaurizio Montecucco¹ and Roberto Caporali², ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose: Early diagnosis and treat-to-target strategies with conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of the…
Abstract Number: 496 • 2015 ACR/ARHP Annual Meeting
Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Increased serum lipid levels in patients being treated with tocilizumab (TCZ) is known from several clinical trials1,2. It is not known whether additional methotrexate…
Abstract Number: 497 • 2015 ACR/ARHP Annual Meeting
Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
Seung Min Jung¹, Ji Yeon Lee¹, Jung Hee Koh¹, Seung-Ki Kwok², Ji Hyeon Ju¹, Chong-Hyeon Yoon¹ and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, predominantly affecting women in their fifth and sixth decades of life. Although population aging increases the…
Abstract Number: 498 • 2015 ACR/ARHP Annual Meeting
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Gerolamo Bianchi¹, Antonio Carletto², Oscar M. Epis³, Crescenzio Scioscia⁴, Angelo Semeraro⁵, Chiara Donati⁶, Laura Bazzichi⁷, Giovanni Lapadula⁸, Luigi Sinigaglia⁹ and Andrea Lo Monaco¹⁰, ¹Div Reumatologia, Ospedale La Colletta, Genoa, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy, ³Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy, ⁴DIM - Sezione di Reuamtologia Università degli Studi di Bari "Aldo Moro", Bari, Italy, ⁵Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ⁶Roche S.p.A., Monza, Italy, ⁷Division of Reumatology, Univeristy of Pisa, Pisa, Italy, ⁸D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ⁹Rheumatology Dep, I.O.G. Pini, Milan, Italy, ¹⁰Ospedale S. Anna, Ferrara, Italy
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the non-adherence to therapy may impair the clinical outcomes, being often associated with the disease flare and…
Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Vidhu Anand¹, Sachit Anand², Sushil Garg³, Maria A. Lopez-Olivo⁴ and Jasvinder A. Singh⁵, ¹University of Minnesota, Minneapolis, MN, ²All India Institute of Medical Sciences, New Delhi, India, ³The University of Minnesota, Minneapolis, MN, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
Abstract Number: 501 • 2015 ACR/ARHP Annual Meeting
Change in RF Titers Reflects RA Disease Activity and Predicts Therapeutic Response during TNF Inhibitor Therapy; Patients with a Continuous Reduction of Serum RF Levels Show Good Response
Takayoshi Owada, Kazuhiro Kurasawa, Yuta Takamura, Yumeko Namiki, Ayae Tanaka, Ryutaro Yamazaki, Harutsugu Okada, Satoko Arai, Reika Maezawa, Keiko Hatanaka and Yoshiki Ishii, Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Serum RF was detected in 26-90% of RA patients, and high-titer RF has been shown a poor prognosis factor in RA and predictor of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].